Sclerostin is a protein produced by osteocytes in the bone that inhibits bone formation. A recent analysis of results from a clinical trial reveals the beneficial effects of romosozumab, an antibody therapy that targets sclerostin, on bone tissue in postmenopausal women with osteoporosis.
From https://jamesjohnson10.blogspot.com/2019/06/study-discusses-beneficial-effects-of.html
from
https://jamesjohnson10.wordpress.com/2019/06/26/study-discusses-beneficial-effects-of-antibody-therapy-that-targets-sclerostin/
No comments:
Post a Comment